Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hereditary Autoinflammatory Diseases | 11 | 2023 | 42 | 3.130 |
Why?
|
Stomatitis, Aphthous | 7 | 2023 | 51 | 1.750 |
Why?
|
Lymphadenitis | 7 | 2023 | 99 | 1.690 |
Why?
|
Pharyngitis | 7 | 2023 | 222 | 1.590 |
Why?
|
Osteomyelitis | 6 | 2023 | 408 | 1.260 |
Why?
|
Familial Mediterranean Fever | 5 | 2022 | 65 | 1.170 |
Why?
|
Fever | 14 | 2023 | 1614 | 1.120 |
Why?
|
Mevalonate Kinase Deficiency | 6 | 2022 | 19 | 0.870 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 2 | 2023 | 545 | 0.790 |
Why?
|
Macrophage Activation Syndrome | 6 | 2024 | 124 | 0.780 |
Why?
|
Scleroderma, Localized | 5 | 2024 | 85 | 0.760 |
Why?
|
Exanthema | 2 | 2022 | 503 | 0.680 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 8 | 2023 | 539 | 0.640 |
Why?
|
Thermometers | 1 | 2018 | 42 | 0.630 |
Why?
|
Biological Products | 4 | 2023 | 947 | 0.620 |
Why?
|
Cryopyrin-Associated Periodic Syndromes | 4 | 2022 | 17 | 0.590 |
Why?
|
Autoimmune Diseases | 4 | 2020 | 2257 | 0.520 |
Why?
|
Body Temperature | 1 | 2018 | 780 | 0.500 |
Why?
|
Coronary Aneurysm | 3 | 2023 | 234 | 0.430 |
Why?
|
Steroids | 1 | 2018 | 938 | 0.430 |
Why?
|
Vasculitis | 3 | 2009 | 525 | 0.430 |
Why?
|
Child | 51 | 2024 | 80917 | 0.390 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 4 | 2022 | 299 | 0.390 |
Why?
|
Tonsillectomy | 3 | 2020 | 281 | 0.380 |
Why?
|
Antirheumatic Agents | 5 | 2023 | 1381 | 0.380 |
Why?
|
Immunity, Innate | 2 | 2022 | 3080 | 0.370 |
Why?
|
Adenoidectomy | 1 | 2012 | 171 | 0.360 |
Why?
|
Behcet Syndrome | 2 | 2023 | 86 | 0.360 |
Why?
|
Autoimmunity | 2 | 2009 | 1361 | 0.360 |
Why?
|
Syndrome | 7 | 2023 | 3273 | 0.330 |
Why?
|
Nod2 Signaling Adaptor Protein | 1 | 2009 | 86 | 0.320 |
Why?
|
Skin Ulcer | 2 | 2023 | 130 | 0.320 |
Why?
|
Scleroderma, Systemic | 3 | 2024 | 346 | 0.310 |
Why?
|
Autoantibodies | 5 | 2023 | 2121 | 0.310 |
Why?
|
Adenosine Deaminase | 2 | 2021 | 253 | 0.300 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 6 | 1994 | 812 | 0.300 |
Why?
|
Dermatomyositis | 3 | 2024 | 259 | 0.280 |
Why?
|
Minocycline | 1 | 2008 | 170 | 0.280 |
Why?
|
Granuloma | 1 | 2009 | 329 | 0.280 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 271 | 0.280 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2023 | 621 | 0.270 |
Why?
|
Interleukin-1 | 5 | 2023 | 1252 | 0.270 |
Why?
|
NF-kappa B | 4 | 2023 | 2494 | 0.260 |
Why?
|
Membrane Proteins | 2 | 2022 | 7876 | 0.260 |
Why?
|
Comparative Effectiveness Research | 2 | 2023 | 714 | 0.260 |
Why?
|
Cytidine Deaminase | 2 | 2007 | 249 | 0.260 |
Why?
|
Rheumatology | 2 | 2022 | 617 | 0.260 |
Why?
|
Chronic Disease | 9 | 2024 | 9384 | 0.250 |
Why?
|
Adolescent | 32 | 2024 | 89169 | 0.240 |
Why?
|
Child, Preschool | 23 | 2024 | 42669 | 0.240 |
Why?
|
Severity of Illness Index | 7 | 2024 | 15949 | 0.220 |
Why?
|
Consensus | 9 | 2024 | 3211 | 0.220 |
Why?
|
Colchicine | 2 | 2022 | 257 | 0.220 |
Why?
|
Sarcoidosis | 1 | 2009 | 535 | 0.220 |
Why?
|
Nasopharyngitis | 1 | 2023 | 10 | 0.220 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2021 | 1657 | 0.210 |
Why?
|
Immunoglobulin Class Switching | 4 | 2007 | 289 | 0.210 |
Why?
|
Humans | 84 | 2024 | 768171 | 0.210 |
Why?
|
Arthritis | 1 | 2008 | 684 | 0.200 |
Why?
|
Raynaud Disease | 1 | 2023 | 81 | 0.200 |
Why?
|
Facial Hemiatrophy | 1 | 2022 | 24 | 0.200 |
Why?
|
Synovial Fluid | 2 | 2021 | 393 | 0.190 |
Why?
|
Osteitis | 1 | 2021 | 33 | 0.190 |
Why?
|
Hyperostosis | 1 | 2021 | 29 | 0.190 |
Why?
|
Acquired Hyperostosis Syndrome | 1 | 2021 | 34 | 0.190 |
Why?
|
Antipyretics | 3 | 2020 | 23 | 0.190 |
Why?
|
Retroperitoneal Fibrosis | 1 | 2001 | 42 | 0.190 |
Why?
|
Adrenal Cortex Hormones | 4 | 2020 | 1886 | 0.180 |
Why?
|
Inflammation | 7 | 2023 | 10873 | 0.180 |
Why?
|
Transcription Factor RelA | 2 | 2023 | 253 | 0.180 |
Why?
|
Turkey | 2 | 2021 | 256 | 0.180 |
Why?
|
Nucleotidyltransferases | 1 | 2022 | 242 | 0.170 |
Why?
|
Interleukin-4 | 1 | 2004 | 1156 | 0.170 |
Why?
|
Synovitis | 1 | 2021 | 217 | 0.170 |
Why?
|
Interferon Type I | 1 | 2023 | 569 | 0.170 |
Why?
|
Alcohol Drinking | 3 | 2024 | 4045 | 0.160 |
Why?
|
Botulinum Toxins, Type A | 1 | 2023 | 238 | 0.160 |
Why?
|
Eosinophilia | 1 | 2023 | 556 | 0.150 |
Why?
|
Cell Polarity | 1 | 2021 | 639 | 0.150 |
Why?
|
Retrospective Studies | 15 | 2024 | 81760 | 0.150 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2020 | 667 | 0.140 |
Why?
|
B-Lymphocytes | 5 | 2023 | 4793 | 0.140 |
Why?
|
Methotrexate | 3 | 2019 | 1721 | 0.140 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2023 | 2171 | 0.140 |
Why?
|
Vaccines, Attenuated | 1 | 2018 | 313 | 0.140 |
Why?
|
Delayed Diagnosis | 1 | 2021 | 467 | 0.140 |
Why?
|
Tamoxifen | 1 | 2001 | 966 | 0.140 |
Why?
|
Male | 34 | 2024 | 364731 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 549 | 0.130 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2021 | 3115 | 0.130 |
Why?
|
Oral Ulcer | 1 | 2017 | 96 | 0.130 |
Why?
|
Female | 37 | 2024 | 397187 | 0.130 |
Why?
|
Crohn Disease | 1 | 2009 | 2295 | 0.130 |
Why?
|
Acne Vulgaris | 1 | 2021 | 352 | 0.130 |
Why?
|
Glucocorticoids | 2 | 2019 | 2167 | 0.130 |
Why?
|
Haploinsufficiency | 1 | 2017 | 334 | 0.120 |
Why?
|
Infant | 12 | 2024 | 36535 | 0.120 |
Why?
|
Immunosuppressive Agents | 4 | 2018 | 4206 | 0.120 |
Why?
|
Genes, Dominant | 1 | 2017 | 855 | 0.120 |
Why?
|
Arthralgia | 1 | 2018 | 459 | 0.120 |
Why?
|
Remission Induction | 2 | 2018 | 2410 | 0.120 |
Why?
|
Trans-Activators | 1 | 2004 | 2857 | 0.110 |
Why?
|
Alcohol-Related Disorders | 1 | 2016 | 243 | 0.110 |
Why?
|
Th17 Cells | 1 | 2020 | 791 | 0.110 |
Why?
|
T-Lymphocytes, Helper-Inducer | 3 | 2023 | 977 | 0.110 |
Why?
|
Arthritis, Rheumatoid | 3 | 2023 | 3781 | 0.110 |
Why?
|
Spinal Diseases | 1 | 2018 | 561 | 0.110 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 1993 | 171 | 0.110 |
Why?
|
Lung Diseases, Interstitial | 1 | 2022 | 940 | 0.110 |
Why?
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1993 | 94 | 0.110 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2001 | 1536 | 0.100 |
Why?
|
Lung Diseases | 1 | 2023 | 1944 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2018 | 905 | 0.100 |
Why?
|
Immunoglobulin Joining Region | 1 | 1992 | 37 | 0.100 |
Why?
|
Immunoglobulin Constant Regions | 1 | 1992 | 58 | 0.100 |
Why?
|
Adolescent Behavior | 1 | 2020 | 1186 | 0.100 |
Why?
|
Mass Screening | 2 | 2019 | 5458 | 0.100 |
Why?
|
Interleukin-6 | 2 | 2020 | 3229 | 0.100 |
Why?
|
Receptors, Interleukin-1 | 2 | 2022 | 260 | 0.090 |
Why?
|
Counseling | 1 | 2019 | 1554 | 0.090 |
Why?
|
Periodicity | 1 | 2012 | 348 | 0.090 |
Why?
|
Coronary Vessels | 2 | 2017 | 3124 | 0.090 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1993 | 648 | 0.090 |
Why?
|
Boston | 3 | 2021 | 9374 | 0.090 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 13013 | 0.090 |
Why?
|
Vulnerable Populations | 1 | 2016 | 718 | 0.090 |
Why?
|
Anemia, Dyserythropoietic, Congenital | 1 | 2010 | 15 | 0.090 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10266 | 0.090 |
Why?
|
Recurrence | 1 | 2022 | 8509 | 0.080 |
Why?
|
Alcoholism | 1 | 2020 | 1980 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 18065 | 0.080 |
Why?
|
Synovial Membrane | 1 | 1993 | 536 | 0.080 |
Why?
|
Anti-Bacterial Agents | 1 | 2008 | 7477 | 0.080 |
Why?
|
Echocardiography | 3 | 2019 | 5047 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2017 | 4355 | 0.080 |
Why?
|
Quality of Life | 4 | 2023 | 13490 | 0.080 |
Why?
|
Proteins | 2 | 2020 | 6009 | 0.080 |
Why?
|
Immunoglobulin M | 1 | 1993 | 1528 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2023 | 65379 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2271 | 0.080 |
Why?
|
DNA | 1 | 2022 | 7213 | 0.080 |
Why?
|
Disease Progression | 3 | 2023 | 13668 | 0.080 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2008 | 72 | 0.070 |
Why?
|
C-Reactive Protein | 4 | 2022 | 3858 | 0.070 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 434 | 0.070 |
Why?
|
Enzyme Induction | 2 | 2007 | 455 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4712 | 0.070 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2008 | 424 | 0.070 |
Why?
|
Histamine H2 Antagonists | 2 | 2020 | 169 | 0.070 |
Why?
|
Cytokines | 4 | 2023 | 7452 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2008 | 0.070 |
Why?
|
Feasibility Studies | 3 | 2024 | 5315 | 0.070 |
Why?
|
Immunoglobulin G | 4 | 2012 | 4568 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 2 | 2013 | 1810 | 0.070 |
Why?
|
Antibodies, Antinuclear | 1 | 2008 | 342 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2008 | 3814 | 0.070 |
Why?
|
Young Adult | 8 | 2023 | 60066 | 0.070 |
Why?
|
Program Development | 1 | 2012 | 1300 | 0.060 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2008 | 297 | 0.060 |
Why?
|
Registries | 2 | 2019 | 8375 | 0.060 |
Why?
|
Genetic Variation | 2 | 2021 | 6610 | 0.060 |
Why?
|
Signal Transduction | 3 | 2023 | 23648 | 0.060 |
Why?
|
Observer Variation | 2 | 2024 | 2621 | 0.060 |
Why?
|
Prognosis | 5 | 2021 | 30009 | 0.060 |
Why?
|
Mutation | 5 | 2023 | 30237 | 0.060 |
Why?
|
Methylprednisolone | 2 | 2019 | 386 | 0.060 |
Why?
|
Particulate Matter | 1 | 2016 | 2617 | 0.060 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2007 | 547 | 0.060 |
Why?
|
HLA Antigens | 1 | 2009 | 1334 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2020 | 4423 | 0.060 |
Why?
|
STAT6 Transcription Factor | 1 | 2004 | 196 | 0.060 |
Why?
|
Receptors, Interleukin-4 | 1 | 2003 | 66 | 0.050 |
Why?
|
Immunoglobulin E | 2 | 2007 | 1506 | 0.050 |
Why?
|
Peptides | 3 | 1992 | 4354 | 0.050 |
Why?
|
Photogrammetry | 1 | 2023 | 77 | 0.050 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2004 | 294 | 0.050 |
Why?
|
Animals | 15 | 2023 | 169285 | 0.050 |
Why?
|
Adult | 12 | 2023 | 223646 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2024 | 20225 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3929 | 0.050 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7454 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 186 | 0.050 |
Why?
|
Prospective Studies | 6 | 2024 | 54924 | 0.050 |
Why?
|
Recombination, Genetic | 1 | 2007 | 1525 | 0.050 |
Why?
|
Phenotype | 2 | 2020 | 16726 | 0.050 |
Why?
|
Air Pollutants | 1 | 2016 | 2916 | 0.050 |
Why?
|
Antibodies | 3 | 2023 | 2421 | 0.050 |
Why?
|
Risk Assessment | 6 | 2019 | 24318 | 0.050 |
Why?
|
Radiography, Panoramic | 1 | 2022 | 112 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2023 | 609 | 0.050 |
Why?
|
Respiratory Hypersensitivity | 1 | 2003 | 272 | 0.050 |
Why?
|
Administration, Cutaneous | 1 | 2024 | 716 | 0.050 |
Why?
|
Proteomics | 3 | 2023 | 3912 | 0.050 |
Why?
|
Immunoglobulin Light Chains | 2 | 1994 | 289 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2016 | 4543 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7951 | 0.050 |
Why?
|
Information Systems | 1 | 2023 | 400 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2010 | 2592 | 0.040 |
Why?
|
Cimetidine | 1 | 2020 | 76 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2004 | 992 | 0.040 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 6316 | 0.040 |
Why?
|
Mediastinum | 1 | 2001 | 272 | 0.040 |
Why?
|
Molecular Sequence Data | 7 | 1993 | 17623 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2020 | 235 | 0.040 |
Why?
|
Tubulin Modulators | 1 | 2020 | 106 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2019 | 135 | 0.040 |
Why?
|
Virus Diseases | 1 | 2005 | 724 | 0.040 |
Why?
|
Base Sequence | 3 | 2017 | 12422 | 0.040 |
Why?
|
Endocrine System | 1 | 2020 | 113 | 0.040 |
Why?
|
Genes, MHC Class II | 1 | 2020 | 433 | 0.040 |
Why?
|
Lipomatosis | 1 | 2020 | 112 | 0.040 |
Why?
|
Risk Factors | 6 | 2024 | 74944 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2007 | 6231 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4648 | 0.040 |
Why?
|
Immune System Diseases | 1 | 2021 | 253 | 0.040 |
Why?
|
Blood Sedimentation | 1 | 2019 | 236 | 0.040 |
Why?
|
Necrosis | 1 | 2023 | 1616 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 425 | 0.040 |
Why?
|
Neuropeptides | 1 | 2004 | 951 | 0.040 |
Why?
|
Bone Marrow Diseases | 1 | 2020 | 234 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2019 | 251 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2022 | 459 | 0.040 |
Why?
|
Pain | 2 | 2023 | 5099 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26379 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2023 | 924 | 0.040 |
Why?
|
Bacterial Infections | 1 | 2005 | 1397 | 0.040 |
Why?
|
Public Opinion | 1 | 2021 | 486 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15453 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 1049 | 0.030 |
Why?
|
Ferritins | 1 | 2019 | 601 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18415 | 0.030 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
Amino Acid Sequence | 6 | 1993 | 13422 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2021 | 1864 | 0.030 |
Why?
|
Meningitis, Aseptic | 1 | 2016 | 59 | 0.030 |
Why?
|
Serum Amyloid A Protein | 1 | 2016 | 128 | 0.030 |
Why?
|
Th1 Cells | 1 | 2021 | 1042 | 0.030 |
Why?
|
Immune Sera | 2 | 1994 | 605 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 1667 | 0.030 |
Why?
|
Dextran Sulfate | 1 | 2017 | 258 | 0.030 |
Why?
|
Cross Reactions | 3 | 1994 | 828 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 796 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1557 | 0.030 |
Why?
|
Ontario | 1 | 2016 | 403 | 0.030 |
Why?
|
Neck | 1 | 2020 | 736 | 0.030 |
Why?
|
Binding Sites | 1 | 2004 | 6019 | 0.030 |
Why?
|
Urticaria | 1 | 2016 | 151 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1184 | 0.030 |
Why?
|
Cell Line | 2 | 2004 | 15602 | 0.030 |
Why?
|
California | 1 | 2019 | 1438 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2022 | 36741 | 0.030 |
Why?
|
Risk-Taking | 1 | 2020 | 1023 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2016 | 297 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2004 | 12801 | 0.030 |
Why?
|
Prednisone | 1 | 2019 | 1567 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2017 | 19025 | 0.030 |
Why?
|
Mice | 9 | 2012 | 82049 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14729 | 0.030 |
Why?
|
Delphi Technique | 1 | 2018 | 890 | 0.030 |
Why?
|
Fibrosis | 1 | 2001 | 2081 | 0.030 |
Why?
|
Urban Health | 1 | 2016 | 535 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 1993 | 6082 | 0.030 |
Why?
|
Rare Diseases | 1 | 2019 | 631 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2040 | 0.030 |
Why?
|
North America | 1 | 2017 | 1289 | 0.030 |
Why?
|
Antibody Specificity | 2 | 1993 | 1065 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2019 | 939 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2004 | 5797 | 0.030 |
Why?
|
Immunoglobulin Variable Region | 1 | 1993 | 420 | 0.030 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1994 | 355 | 0.030 |
Why?
|
Reference Values | 1 | 2019 | 4939 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3436 | 0.020 |
Why?
|
Particle Size | 1 | 2016 | 1651 | 0.020 |
Why?
|
Antigens | 2 | 2004 | 1443 | 0.020 |
Why?
|
Specialization | 1 | 2017 | 779 | 0.020 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 1992 | 83 | 0.020 |
Why?
|
Treatment Failure | 1 | 2018 | 2661 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1751 | 0.020 |
Why?
|
Contractile Proteins | 1 | 2012 | 240 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2021 | 4280 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 1992 | 283 | 0.020 |
Why?
|
Time Factors | 2 | 2016 | 40220 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4034 | 0.020 |
Why?
|
Metalloendopeptidases | 1 | 2012 | 386 | 0.020 |
Why?
|
Genetic Loci | 1 | 2020 | 2629 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1951 | 0.020 |
Why?
|
Musculoskeletal Diseases | 1 | 2016 | 599 | 0.020 |
Why?
|
Seasons | 1 | 2016 | 1524 | 0.020 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2016 | 783 | 0.020 |
Why?
|
DNA, Complementary | 1 | 1993 | 1989 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4064 | 0.020 |
Why?
|
Skin | 1 | 2024 | 4505 | 0.020 |
Why?
|
Middle Aged | 4 | 2018 | 223487 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2009 | 39354 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2540 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2021 | 22290 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3591 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2434 | 0.020 |
Why?
|
Pedigree | 1 | 2017 | 4539 | 0.020 |
Why?
|
Glycosylation | 1 | 2012 | 1100 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 14164 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2004 | 5804 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 10397 | 0.020 |
Why?
|
Alleles | 1 | 2020 | 6894 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 4415 | 0.020 |
Why?
|
Colitis | 1 | 2017 | 1242 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3628 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 1816 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41753 | 0.020 |
Why?
|
Autoantigens | 1 | 1992 | 890 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2012 | 1133 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4428 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4585 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3706 | 0.020 |
Why?
|
Fibroblasts | 1 | 2017 | 4178 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2235 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 9617 | 0.020 |
Why?
|
Thymus Gland | 1 | 1992 | 1266 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2009 | 412 | 0.020 |
Why?
|
United States | 3 | 2022 | 73039 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14488 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 1992 | 2568 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 4786 | 0.020 |
Why?
|
Logistic Models | 1 | 2021 | 13290 | 0.020 |
Why?
|
Bone and Bones | 1 | 2016 | 2590 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8741 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2202 | 0.020 |
Why?
|
B-Cell Activation Factor Receptor | 1 | 2005 | 12 | 0.020 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2005 | 40 | 0.010 |
Why?
|
Computer Simulation | 1 | 2018 | 6283 | 0.010 |
Why?
|
Incidence | 1 | 2023 | 21538 | 0.010 |
Why?
|
B-Cell Activating Factor | 1 | 2005 | 116 | 0.010 |
Why?
|
Blotting, Western | 1 | 1992 | 5028 | 0.010 |
Why?
|
Peptide Fragments | 2 | 1994 | 5151 | 0.010 |
Why?
|
B-Cell Maturation Antigen | 1 | 2005 | 149 | 0.010 |
Why?
|
Dilatation, Pathologic | 1 | 2005 | 527 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3857 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10101 | 0.010 |
Why?
|
TNF Receptor-Associated Factor 3 | 1 | 2002 | 38 | 0.010 |
Why?
|
TNF Receptor-Associated Factor 2 | 1 | 2002 | 56 | 0.010 |
Why?
|
Rabbits | 3 | 1994 | 4773 | 0.010 |
Why?
|
Lymphoid Tissue | 1 | 2004 | 445 | 0.010 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2005 | 588 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4055 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15869 | 0.010 |
Why?
|
Genetic Complementation Test | 1 | 2002 | 557 | 0.010 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2003 | 558 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9540 | 0.010 |
Why?
|
Protein Conformation | 3 | 1994 | 3956 | 0.010 |
Why?
|
Mice, Transgenic | 2 | 2004 | 9561 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 16044 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2002 | 930 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2012 | 22380 | 0.010 |
Why?
|
Germinal Center | 1 | 2002 | 380 | 0.010 |
Why?
|
Receptor, Insulin | 1 | 2003 | 839 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2002 | 855 | 0.010 |
Why?
|
Models, Molecular | 3 | 1994 | 5402 | 0.010 |
Why?
|
Protein Interaction Mapping | 1 | 2002 | 622 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2002 | 1497 | 0.010 |
Why?
|
Th2 Cells | 1 | 2003 | 1078 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2001 | 20762 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2002 | 3056 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4477 | 0.010 |
Why?
|
Epitopes | 2 | 1994 | 2527 | 0.010 |
Why?
|
Lymphocytes | 1 | 2004 | 2614 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2002 | 1495 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2003 | 2451 | 0.010 |
Why?
|
Bence Jones Protein | 1 | 1994 | 19 | 0.010 |
Why?
|
Myeloma Proteins | 1 | 1994 | 71 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2009 | 4978 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2002 | 3740 | 0.010 |
Why?
|
Immunochemistry | 1 | 1993 | 116 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2003 | 2892 | 0.010 |
Why?
|
Up-Regulation | 1 | 2002 | 4149 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2009 | 14783 | 0.010 |
Why?
|
Goats | 1 | 1992 | 166 | 0.010 |
Why?
|
Antigens, CD | 1 | 2002 | 4035 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2002 | 5505 | 0.010 |
Why?
|
Peptide Mapping | 1 | 1991 | 260 | 0.010 |
Why?
|
Binding, Competitive | 1 | 1992 | 1142 | 0.010 |
Why?
|
Protein Binding | 1 | 2002 | 9343 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1992 | 1435 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1994 | 2748 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1993 | 2179 | 0.000 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1992 | 1535 | 0.000 |
Why?
|
Aged | 2 | 2016 | 171502 | 0.000 |
Why?
|